"We think that the biggest threat to medtech revenue growth is a decline in elective procedures," the analyst said, adding that this trend is driven by hospitals cutting back on or stopping elective procedures as they prepare for and focus on COVID-19 patients, and by patients deferring elective procedures due to fears of exposure to the virus.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,